JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD. (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - December 23, 2021 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
Prostate and Kidney Cancer Studies Awaiting Determinnation from FDA
Sarmad Sadeghi, MD, PhD, discusses studies that are awaiting determinations fom the FDA.
Author: Annual-Meeting
Added: 08/21/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2019 Category: Cancer & Oncology Source Type: podcasts
JAMA Oncology : Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
Interview with Suzanne L. Topalian, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - July 25, 2019 Category: General Medicine Source Type: podcasts
Most Anticipated Trial Results Regarding Biomarkers in RCC
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
Strategies for Treating RCC in the 2nd Line Setting
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
Perspective on Treating Newly Diagnosed RCC Patients
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients.
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
Studies in Sarcomatoid RCC and Urothelial Cancer
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell cancer and urothelial cancer.
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
